Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks
CROI 22025 SF March 9-12
Laurie A. VanderVeen1*, Silvia Chang1, Lisa Selzer1, Tracy L. Diamond2, Ernest Asante-Appiah2, Cyril Llamoso2, Martin S. Rhee1, Christian Callebaut1
1Gilead Sciences, Inc., Foster City, CA, USA; 2Merck & Co., Inc., Rahway, NJ, USA
*Presenting author
